Drug Trial Radar · NCT04918186
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
May 3, 2022
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Canadian Cancer Trials GroupResearch network
- Sponsor type
- Research network
- Collaborators
- Cancer Research Institute, New York City; AstraZeneca; BioAtla, Inc.
- First posted
- Jun 8, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in the study.
Conditions
- Ovarian Cancer
Interventions
DurvalumabDrug
1500mg IV, 60 min day 1 every 4 weeks
BA3011Drug
IV
BA3021Drug
IV
ENB003Drug
IV
ToripalimabDrug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- To efficiently identify based on objective response rate (ORR), by investigator assessment using RECIST 1.1, promising immunotherapy combinations for the treatment of high grade serous ovarian cancer for later validation in randomized trialsTime frame: 36 months
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
The University of Chicago Medical Center
Chicago, Illinois · Recruiting
BCCA - Kelowna
Kelowna, British Columbia, Canada · Not yet recruiting
BCCA - Vancouver
Vancouver, British Columbia, Canada · Not yet recruiting
Odette Cancer Centre
Toronto, Ontario, Canada · Not yet recruiting
University Health Network
Toronto, Ontario, Canada · Not yet recruiting
CHUM-Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.